ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LEVEMIR
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

LEVEMIR Rx

Generic Name and Formulations:
Insulin detemir (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol.

Company:
Novo Nordisk

Therapeutic Use:

Indications for LEVEMIR:

Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed.

Limitations Of use:

Not for treating diabetic ketoacidosis.

Limitations Of use:

Not for treatment of diabetic ketoacidosis.

Adults and Children:

May be given once daily with evening meal or at bedtime or twice-daily (in the AM and PM). SC inj only into thigh, abdominal wall, or upper arm. <2yrs: not recommended. ≥2yrs, type 1 diabetes: starting dose should be ⅓ of total daily insulin requirements; rapid-acting or short-acting, pre-meal insulin should be used to satisfy remainder of daily insulin requirements. Insulin-naive, type 2 diabetic adults inadequately controlled on oral antidiabetics: initially 10 Units (or 0.1–0.2 Units/kg) once daily in the evening or divided into twice daily regimen; inadequately controlled on GLP-1 receptor agonist: initially 10 Units once daily in the evening. Switching from another basal insulin: dose should be the same on a unit-to-unit basis; may need more insulin detemir when switching from NPH (see full labeling).

Warnings/Precautions:

Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Do not mix or dilute with other insulins. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine.

Adverse Reactions:

Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.

How Supplied:

Vials (10mL)—1; FlexTouch (3mL)—1

Sign Up for Free e-newsletters